Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …

This systematic review assesses current molecular targeted therapies for glioblastoma
multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA …

Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest
malignant types of primary astrocytoma with a poor prognosis. At present, the standard of …

Although brain tumours have been documented and recorded since the nineteenth century,
2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term …

Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It
affects an enormous number of patients every year and the survival is approximately 8 to 15 …

Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor, has
a high mortality rate despite extensive efforts to develop new treatments. GBM exhibits both …

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5‐
year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique …

Introduction The increasingly detailed genetic characterization of glioblastoma (GBM) has
failed to translate into meaningful breakthroughs in treatment. This is likely to be attributed to …

Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest
challenges in the management of cancer patients worldwide, despite notable recent …